Fast Locator 2011-2012: UPM Pharmaceuticals, Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: UPM Pharmaceuticals, Inc.



UPM Pharmaceuticals® is a Baltimore-based, independent provider of contract drug development, cGMP manufacturing and analytical testing services. We specialize in oral routes of administration with a focus on solid dosage forms. With our commitment to efficiency, timeliness and flexibility, we deliver industry-savvy, customer-focused services. Our scientists have extensive experience with product development challenges such as low dose content uniformity, high dose compressibility and controlled drug release rates. UPM has be helping clients successfully navigate the drug development continuum for the past two decades. Our extensive equipment train, experienced professional staff and our commitment to quality translates into success for each and every project.


Regions where services are provided:

Asia, North America, Europe, Latin America, Japan, & Middle East


Outsourcing serivces provided:

Development and Phase I/IICTM

  • Drug delivery
  • Solid dose, semisolids, and liquids development
  • Process development-small molecule

Commercial Manufacturing

  • Ingredient processing
  • Semisolids and liquids
  • Solid dosage forms
  • Specialty dosage forms

Analytical Services

  • Chemistry and stability
  • Particle characterization

Packaging and Logistics

  • Clinical labels
  • Clinical packaging and distribution

Website:

www.upm-inc.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here